“We are pleased that our external research program serves as a model for the industry”

The MTA program was created in 2013 by ChromaDex co-founder Frank Jaksch and became the ChromaDex External Research Program (CERP) in 2019. Over the years the program has grown to 235 scientists, physicians and researchers independents in 182 institutions and 33 countries. . This has led to more than 250 MTAs using various ChromaDex materials, including the company’s Niagen-branded ingredient nicotinamide riboside.

Nicotinamide riboside (NR) is an effective precursor to the essential cellular coenzyme, nicotinamide adenine dinucleotide (NAD+), with implications for a range of endpoints including cellular health, cellular energy, heart health, muscle and brain health.

“CERP is an important component of ChromaDex’s philanthropy. Our multidisciplinary and cross-functional in-house scientists not only provide high-quality research material, but also create community and multidimensional support for the researchers in our program,”​ said Dr. Yasmeen Nkrumah-Elie, Global Director of Research and Development for External Research at ChromaDex.

“Our goal is to set the standard of excellence in industry-academic relationships and collaborations, and our program measures demonstrate that we are achieving this goal.”

“We think it could be replicated”

Speaking to NutraIngredients-USA, Dr. Andrew Shao, Senior Vice President of Global Regulatory and Scientific Affairs at ChromaDex, explained: “We don’t know of anyone else in the industry our size that has a branded external research program like we do.​.

“We are happy to serve as a role model for the industry. We believe this could be replicated. However, this requires a considerable investment and a lot of foresight.

To date, the company has donated nearly $2 million from Niagen to researchers around the world for various scientific projects, most of which are funded by third parties and not by ChromaDex.

“One area that we have developed with CERP is helping to develop intellectual property,” says Dr. Shao. “One of the things we do is provide the test materials to investigators for free in exchange for access to intellectual property that may be generated as a result of the research. So there is a commercial benefit here in addition to advancing research on nicotinamide riboside and NAD.

Watch the full interview with Dr. Shao above.

Comments are closed.